Table 3.
Univariate analyses of various clinicopathological parameters in relation to survival of patients with bladder cancer
| Clinical features | N |
OS |
PFS |
||
|---|---|---|---|---|---|
| 3-year survival (%) | P | 3-year survival (%) | P | ||
|
Sex |
|
|
|
|
|
| Male |
87 |
34 (39.1) |
0.08 |
24 (27.6) |
0.08 |
| Female |
39 |
22 (56.4) |
18 (46.2) |
||
|
Age (years) |
|
|
|
|
|
| ≤70 |
55 |
20 (36.4) |
0.1 |
13 (23.6) |
0.1 |
| >70 |
71 |
36 (50.7) |
29 (40.8) |
||
|
Stage |
|
|
|
|
|
| Ta |
48 |
30 (62.5) |
0.006 |
26 (54.2) |
0.008 |
| T1 |
46 |
22 (47.8) |
12 (26.1) |
||
| ≥T2 |
32 |
4 (12.5) |
4 (12.5) |
||
|
Grade |
|
|
|
|
|
| LMP |
32 |
18 (56.2) |
0.02 |
17 (53.1) |
0.03 |
| LG |
43 |
21 (48.8) |
15 (34.9) |
||
| HG |
51 |
17 (33.3) |
10 (19.6) |
||
|
Carcinoma in situ |
|
|
|
|
|
| Yes |
26 |
16 (61.5) |
0.01 |
12 (46.2) |
0.02 |
| No |
100 |
40 (40.0) |
30 (30.0) |
||
|
miR-100 |
|
|
|
|
|
| High |
48 |
33 (68.8) |
<0.001 | 26 (54.2) |
0.001 |
| Low | 78 | 23 (29.5) | 16 (20.5) | ||